Table 2.
Outcome | Vaccinated Cases (n = 235) | Unvaccinated Cases (n = 479) | P |
---|---|---|---|
Supplemental oxygen therapy (standard flow oxygen, high-flow nasal cannula, non-invasive ventilation, or invasive mechanical ventilation) | 155 (66%) | 319 (67%) | .93 |
High-flow nasal cannula and/or non-invasive ventilation | 19 (8%) | 61 (13%) | .08 |
Invasive mechanical ventilation | 14 (6%) | 54 (11%) | .03 |
Acute vasopressor use | 11 (5%) | 49 (10%) | .02 |
Acute renal replacement therapy | 0/226a (0%) | 3/458a (1%) | .55 |
Acute organ support (high-flow nasal cannula, non-invasive ventilation, invasive mechanical ventilation, renal replacement therapy, or vasopressor use) | 35 (15%) | 122 (25%) | <.001 |
Intensive care unit admission | 27 (11%) | 107 (22%) | <.001 |
Death | 5 (2%) | 12 (3%) | .96 |
aPatients on chronic renal replacement therapy before their influenza illness were not eligible for acute renal replacement therapy and hence were removed from the denominator for this outcome. Chronic renal replacement therapy was received by 9 vaccinated cases and 21 unvaccinated cases.